title: Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
abstract: Maropitant (Cerenia), a selective neurokinin(1) receptor antagonist, was evaluated for efficacy and safety in prevention of vomiting due to motion sickness in dogs in two randomized clinical trials. One-hundred eighty-nine dogs with a history of motion sickness were enrolled at 26 veterinary clinics (across 12 US states) across the two trials; of these, 163 were fully evaluable, 19 were evaluable only for safety, and seven were not evaluable. Each trial used a two-period crossover design. Each dog was treated orally with placebo or maropitant (minimum dose of 8 mg/kg body weight using unit dosing) tablets at approximately 2 h (Trial 1) or 10 h (Trial 2) before an automobile ride of approximately 60 min, during which dogs were observed for signs of motion sickness. Following a 10-14-day washout period, each dog was administered the opposite treatment and taken for another journey (same route, driver and vehicle). Maropitant reduced the occurrence of vomiting compared to placebo by 86.1% or 76.5% when given approximately 2 or 10 h prior to travel, respectively. No significant clinical signs were observed after maropitant treatment. Maropitant was safe and effective in preventing vomiting due to motion sickness in dogs when administered at a minimum dose of 8 mg/kg body weight as oral tablets 2 or 10 h prior to travel.
authors.affiliation: Veterinary Medicine Research & Development, Pfizer Inc, Kalamazoo, MI 49001, USA. george.a.conder@pfizer.com
authors.forename: G A
authors.initials: GA
authors.lastname: Conder
authors.forename: H S
authors.initials: HS
authors.lastname: Sedlacek
authors.forename: J F
authors.initials: JF
authors.lastname: Boucher
authors.forename: R G
authors.initials: RG
authors.lastname: Clemence
mesh_terms: D000818:Animals; D018592:Cross-Over Studies; D004285:Dogs; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D008297:Male; D009041:Motion Sickness / Q000150:complications / Q000662:veterinary*; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*
chemical_list: D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines; C518176:maropitant